Tom Cohen

Patients Enter Clinic for Phase III mRNA Immunotherapy for High Risk Melanoma

—

by

Tom Cohen
in

The trial will test the world’s first mRNA-based personalised immunotherapy for melanoma.

Read More

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *